Last reviewed · How we verify

Variant-adapted BNT162b2 (Omicron XBB.1.5) 10 microgram dose — Competitive Intelligence Brief

Variant-adapted BNT162b2 (Omicron XBB.1.5) 10 microgram dose (variant-adapted-bnt162b2-omicron-xbb-1-5-10-microgram-dose) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: mRNA vaccine. Area: Immunology.

marketed mRNA vaccine SARS-CoV-2 spike protein Immunology Live · refreshed every 30 min

Target snapshot

Variant-adapted BNT162b2 (Omicron XBB.1.5) 10 microgram dose (variant-adapted-bnt162b2-omicron-xbb-1-5-10-microgram-dose) — Pfizer.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Variant-adapted BNT162b2 (Omicron XBB.1.5) 10 microgram dose TARGET variant-adapted-bnt162b2-omicron-xbb-1-5-10-microgram-dose Pfizer marketed mRNA vaccine SARS-CoV-2 spike protein
Casirivimab and Imdevimab Drug Combination Casirivimab and Imdevimab Drug Combination Mansoura University Hospital marketed Monoclonal antibody combination (SARS-CoV-2 neutralizing antibodies) SARS-CoV-2 spike protein receptor-binding domain
COVID-19 vaccination COVID-19 vaccination University Medical Center Groningen marketed vaccine SARS-CoV-2 spike protein
The Pfizer mRNA-based BNT162b2 vaccine The Pfizer mRNA-based BNT162b2 vaccine dafna yahav marketed mRNA vaccine SARS-CoV-2 spike protein (S protein)
mRNA-1273 Variant-containing Formulation mRNA-1273 Variant-containing Formulation ModernaTX, Inc. marketed mRNA vaccine SARS-CoV-2 spike protein (variant-specific)
COVID-19 mRNA vaccine COVID-19 mRNA vaccine Vaccine Company, Inc. marketed mRNA vaccine SARS-CoV-2 spike protein (S protein)
COMIRNATY intramuscular injection comirnaty-intramuscular-injection Pfizer marketed mRNA vaccine SARS-CoV-2 spike protein

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (mRNA vaccine class)

  1. Pfizer · 12 drugs in this class
  2. ModernaTX, Inc. · 11 drugs in this class
  3. BioNTech SE · 5 drugs in this class
  4. Jules Bordet Institute · 5 drugs in this class
  5. Tan Tock Seng Hospital · 2 drugs in this class
  6. Clover Biopharmaceuticals AUS Pty · 1 drug in this class
  7. CanSino Biologics Inc. · 1 drug in this class
  8. Assistance Publique - Hôpitaux de Paris · 1 drug in this class
  9. CSPC Megalith Biopharmaceutical Co.,Ltd. · 1 drug in this class
  10. Jens D Lundgren, MD · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Variant-adapted BNT162b2 (Omicron XBB.1.5) 10 microgram dose — Competitive Intelligence Brief. https://druglandscape.com/ci/variant-adapted-bnt162b2-omicron-xbb-1-5-10-microgram-dose. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: